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The care for patients with acute ischemic stroke has been revolutionized by the clinical application 
of fibrinolysis. Intravenous recombinant tissue plasminogen activator (rt-PA) has been proven 
to improve functional outcomes following acute ischemic stroke and can be administered 
to a select group of patients up to 4.5 h after symptom onset. Time from symptom onset to 
thrombolysis is the most important determinant of the success of treatment, with greatest 
efficacy if given within 90 min. Hospitals should implement standardized processes and protocols 
for acute stroke to guide immediate patient assessment, brain imaging, drug administration, 
and post-thrombolysis care. In this article we review the clinical application of thrombolysis, 
care of acute stroke patients, current evidence regarding fibrinolysis, and future direction of 
penumbral imaging to select candidates for reperfusion therapies.
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rhage, which occurred in 6.4% of patients treated with rt-PA versus 
0.6% of patients who received placebo, but it did not result in an 
increase in mortality among rt-PA-treated patients. Efficacy was 
greatest for patients treated within 90 min of symptom onset. For 
patients treated within 90 min the odds ratio for complete recovery 
was 2.11 compared with an odds ratio of 1.69 for patients treated 
within 91–180 min (Marler et al., 2000). Functional benefit was 
sustained at 1 year (Kwiatkowski et al., 1999). Subgroup analyses 
confirmed that the efficacy of intravenous rt-PA extended to all 
patients meeting the trial inclusion and exclusion criteria, including 
older patients with severe strokes at presentation (NINDS rt-PA 
Stroke Study Group , 1995).
Shortly  after  publication  of  the  NINDS  trial,  rt-PA  was 
approved for intravenous use in patients with acute ischemic 
stroke in the USA mostly following the patient selection crite-
ria of NINDS study. An additional radiological exclusion crite-
rion was added based on the finding that the presence of large 
early ischemic changes on baseline CT scan was associated with 
higher risk of symptomatic intracranial hemorrhage and results 
from earlier European studies that suggested poorer outcomes in 
patients with multilobar low attenuation changes(von Kummer 
and Hacke, 1992) which had led to the exclusion of these patients 
from  subsequent  European  trials.  Since  then,  treatment  with 
intravenous rt-PA has gained acceptance across the globe and 
its effectiveness has been confirmed in multiple post-marketing 
observational studies.
The largest of these observational studies has been the SITS-
MOST (Wahlgren et al., 2007), which enrolled nearly 6,500 patients 
from 14 European countries. Intravenous fibrinolysis with rt-PA 
was at least as safe and effective in routine clinical practice as it had 
been in the randomized trials (Wahlgren et al., 2007; Wahlgren et al., 
2008b). Over three-quarters of treated patients had moderate to 
severe strokes at baseline and 55% were independent at 3 months 
despite only 10.6% being treated within 90 min (versus half of the 
rt-PA group in the NINDS trial). Even centers with limited experi-
ence on the administration of fibrinolysis for acute stroke achieved 
good results when adhering to the accepted indications and con-
The concept of pharmacological fibrinolysis for the treatment 
of acute ischemic stroke developed from the finding that early 
reperfusion improved outcomes in various experimental animal 
models of intracranial vessel occlusion and the recognition that 
the mechanisms for endogenous fibrinolysis in humans are often 
insufficient to prevent brain infarction in many patients (Meschia 
et al., 2002). The clinical application of fibrinolysis revolutionized 
ischemic stroke care by offering an effective treatment for a disease 
in which previously all medical efforts were focused on prevention 
of recurrent events, avoidance of secondary complications, and 
rehabilitation.
MechanisMs of fibrinolysis
When a clot is formed, a plasma protein called plasminogen gets 
trapped within it. The injured tissues and vascular endothelium 
then slowly release tissue plasminogen activator (t-PA) which in 
turn converts plasminogen to plasmin. Plasmin is a potent pro-
teolytic enzyme that digests fibrin (the main protein component 
of the clot) into soluble fragments (fibrin degradation products). 
This process ensures the clot dissolution and protects blood flow, 
particularly in the microcirculation.
fibrinolysis for the treatMent of ischeMic stroke
the evidence
Early intravenous administration of recombinant tissue plasmino-
gen activator (rt-PA, Alteplase) has been proven to improve func-
tional outcome after acute ischemic stroke (Adams et al., 2007). The 
pivotal trial leading to the international approval of intravenous 
rt-PA for the treatment of cerebral ischemia was the NINDS rt-PA 
Stroke Study (NINDS rt-PA Stroke Study Group , 1995). In this 
trial, 624 patients were randomized to receive intravenous rt-PA 
(0.9 mg/kg, maximum 90 mg) or placebo within 3 h of stroke 
symptom onset. Treatment with intravenous rt-PA was associated 
with at least 30% increase in the chances of achieving functional 
independence  with  complete  or  nearly  complete  neurological 
recovery at 3 months (NINDS rt-PA Stroke Study Group , 1995). 
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tion and treatment. Hospitals should monitor their performance to 
recognize areas for improvement and to ensure consistent compli-
ance with the recommended time metrics (Table 1).
Strict adherence to the prescribed criteria for patient selection 
is crucial to avoid complications and optimize the likelihood of 
benefit from intravenous fibrinolysis. Table 2 presents the indi-
cations  and  contraindications  for  treatment  with  intravenous 
rt-PA. Notice that some additional contraindications should be 
respected when contemplating the use of rt-PA between 3 and 4.5 h. 
Treatment in patients without a suspected coagulopathy (e.g., no 
traindications. The risk of intracranial hemorrhage, defined using 
various criteria, was acceptably low. Substantial neurological decline 
from brain hemorrhage only occurred in 1.7% of patients.
Although intravenous fibrinolysis has become standard of care 
for emergency treatment of patients with acute ischemic stroke, 
only a small minority of these patients receive the therapy. The 
main reason for the limited application of this effective intervention 
in clinical practice is that patients often arrive to the Emergency 
Department too late. As a consequence, there has been a lot of 
interest in extending the therapeutic window for acute reperfusion 
therapies, including intravenous rt-PA.
A pooled analysis of six major trials evaluating the effectiveness 
of intravenous rt-PA for acute ischemic stroke within up to 6 h 
from symptom onset suggested that fibrinolysis could produce 
clinical benefit when administered beyond 3 h (Hacke et al., 2004). 
In fact, this analysis showed that the benefit was much greater 
over the first 90 min from symptom onset, but much more simi-
lar when time to treatment was 91–180 and 181–270 min. These 
findings provided the rationale for the design of the ECASS III 
trial, a multi-center, randomized trial conducted in Europe to 
evaluate intravenous rt-PA versus placebo administered between 
3 and 4.5 h after onset of ischemic stroke symptoms (Hacke et al., 
2008). A total of 821 patients were enrolled, nearly one-third more 
than in the NINDS trial. Treatment with rt-PA was associated 
with a significant improvement in the rate of favorable functional 
outcome using various scales. Overall, the chances to regain full 
independence were 28% higher among patients treated with rt-PA 
and 14 patients had to be treated for one additional patient to 
achieve a favorable outcome. Mortality was not significantly dif-
ferent between the groups, but slightly higher in the placebo arm. 
The rate of symptomatic intracranial hemorrhage as defined by 
the NINDS criteria was 7.9% in the rt-PA group (versus 6.4% in 
the NINDS trial), but only 2.4% of them were considered to have 
worsened because of the bleeding. A subsequent analysis con-
firmed the efficacy of rt-PA in various subgroups treated within 
the 3–4.5 h window, including patients of older age and across 
all severities of stroke (Bluhmki et al., 2009). Intravenous fibri-
nolysis with rt-PA within 3 and 4.5 h was also shown to be safe in 
large European observational study (SITS-ISTR) which included 
over 650 patients treated in that time window (Wahlgren et al., 
2008a). Therefore, intravenous rt-PA should be considered for 
selected patients with symptom duration between 3 and 4.5 h. It 
should be noted that there are additional exclusion criteria for 
the 3–4.5 h time window, as patients with certain characteristics 
were not studied. These include age >80 years, very severe deficits 
at onset (NIHSS >25), combination of history of previous stroke 
and diabetes mellitus, and oral anticoagulation regardless of INR 
at presentation.
Patient evaluation and selection
Acute stroke patients must be evaluated emergently for consid-
eration of reperfusion treatments. Hospitals need to implement a 
stroke code process to streamline immediate patient assessment, 
brain imaging, and drug administration. Development of critical 
care pathways (ideally starting from assessment in the field by para-
medics or other first responders), easily accessible written protocols, 
and order sets is highly useful to ensure rapid and effective evalua-
Table 1 | Target times from acute stroke presentation to fibrinolytic 
treatment.
Step of care  Target time
Evaluation by physician  10 min
Brain imaging  25 min
Interpretation of brain imaging (door-to-interpretation)  45 min
Start of fibrinolysis (door-to-needle)  60 min
Table 2 | Indications and contraindications for intravenous rt-PA in acute 
ischemic stroke.
Indications
Diagnosis of ischemic stroke causing a measurable neurological deficit
Onset of symptoms <4.5 h before initiation of treatment
CoNTrAINdICATIoNS
Clinical
  Sustained hypertension above 180/110 mm Hg
  Symptoms suggestive of subarachnoid hemorrhage
  Previous history of intracranial hemorrhage
  ST elevation myocardial infarction within the previous 3 months
  Major head trauma or stroke within the previous 3 months
  Major surgery within the previous 14 days
  Gastrointestinal or urinary tract hemorrhage within the previous 21 days
  Arterial puncture at a non-compressible site within the previous 7 days
  Active bleeding or acute traumatic fracture on examination
  Seizure at onset with suspected postictal deficits
  Minor or rapidly improving neurological deficits
radiological
  Head CT showing hemorrhage or multilobar infarction (i.e.,  
  hypodensity involving >1/3 of the cerebral hemisphere
Laboratory
  Oral anticoagulation with INR >1.7*
  Heparin within previous 48 h with elevated current aPTT 
  Platelet count <100,000 per mm3
  Blood glucose level <50 mg/dL (2.7 mmol/L) at presentation with
  improving deficits following correction of hypoglycemia
Additional contraindications for treatment between 3 and 4.5 h
  Age >80 years
  Very severe deficits at onset (NIHSS score >25)
  Combination of previous stroke and diabetes mellitus
*Oral anticoagulation regardless of current INR should be considered a contrain-
dication for treatment between 3 and 4.5 h.www.frontiersin.org  October 2010  | Volume 1  | Article 139  |  3
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and sulcal effacement. However, these signs do not have the same 
implication as areas of definite hypodensity because they probably 
indicate focal tissue edema rather than established infarction (Muir 
et al., 2006). Interpretation of brain imaging should be performed 
by a physician with expertise reading brain scans, but formal train-
ing in neuroradiology is not required.
Adequate control of blood pressure before, during and after 
administration of intravenous fibrinolysis must be achieved to 
reduce the risk of intracranial bleeding. Table 3 summarizes the 
recommendations for blood pressure control. Most stroke special-
ists deem administration of fibrinolysis unsafe for patients who 
require sodium nitroprusside infusion to lower the blood pressure 
below 185/110 mm Hg in the Emergency Department.
adMinistration of fibrinolysis and Post-fibrinolysis care
Infusion of the fibrinolytic agent should be started in the Emergency 
Department without delay as soon as the patient is determined 
to be a good treatment candidate. The dose of rt-PA is 0.9 mg/
kg (maximum 90 mg) over 60 min with 10% of the total dose 
given as a bolus over 1 min. After fibrinolysis, the patient should 
be admitted to a Stroke Unit for strict neurological monitoring 
by specialized nurses. Post-fibrinolytic management should be 
recent or current administration of anticoagulants, no history of 
thrombocytopenia, end-stage liver disease or hematologic disorder) 
should not be delayed for laboratories with long turnaround times. 
Thrombolysis can be safely administered in these patients before 
the results of clotting tests are available (Rost et al., 2009). Other 
neurologic conditions can mimic ischemic stroke (e.g., migraine, 
seizure, or conversion disorder), but fear of misdiagnosis should 
not prevent initiation of intravenous thrombolysis if the clini-
cian has reasonable concern for acute ischemic stroke. The risk of 
intracranial hemorrhage in those treated with intravenous rt-PA 
who present with acute neurologic symptoms that are found to be 
caused by other conditions is not well studied, but appears to be 
low. A recent retrospective study found zero instances of intrac-
ranial hemorrhage in patients with stroke mimics (Chernyshev 
et al., 2010).
The importance of careful determination of time of symptom 
onset cannot be overemphasized. Current guidelines on rt-PA 
administration are based on the definition of symptom onset as 
the last time that the patient was symptom-free or at his/her previ-
ous baseline (Adams et al., 2007). For patients who wake up with 
symptoms, the time of onset is considered the last time the patient 
was awake and without the symptoms. A recent transient ischemic 
attack similar to the current symptoms is generally not considered 
a contraindication for fibrinolysis; the clock can be reset to the time 
of onset of the new symptoms as long as there is clear knowledge 
that the previous symptoms resolved fully.
Some factors initially listed among the exclusion criteria for 
intravenous fibrinolysis in the seminal trials are no longer consid-
ered to be contraindications in practice. For instance, the report 
of a seizure at the onset of deficits should not preclude fibrinolysis 
as long as the treating physician is convinced that the persist-
ent deficits are secondary to a stroke and not merely a postictal 
phenomenon (Adams et al., 2007). A similar reasoning might 
applied to hypoglycemic patients who fail to improve after admin-
istration of dextrose. One should also be careful when deciding 
not to treat a stroke patient with fibrinolysis because of mild or 
rapidly improving symptoms. All too often, these patients sub-
sequently suffer permanent disability from those strokes (Barber 
et al., 2001).
Interpretation of brain imaging in the emergency setting has 
the primary objective of excluding intracranial hemorrhage. Non-
contrast CT scan of the head is sufficient for this goal and emer-
gency treatment should not be delayed in order to obtain more 
advanced imaging modalities (such as multimodality MRI and 
multimodality CT) (Adams et al., 2007). Apart from hemorrhage, 
only the presence of multilobar hypodensity (involving more than 
1/3 of the cerebral hemisphere) should be considered a radiologi-
cal contraindication for fibrinolysis (Figure 1). Other CT findings 
may have prognostic value but they do not negate the benefit of 
fibrinolysis and should not preclude its use (Figure 2). For instance, 
the presence of a hyperdense middle cerebral artery sign is associ-
ated with worse prognosis (Qureshi et al., 2006) and higher risk of 
hemorrhage after fibrinolysis (Derex et al., 2005), but intravenous 
rt-PA can still be useful for these patients (Qureshi et al., 2006). 
Other early signs of brain ischemia can often be seen when the CT 
scan is assessed in detail, such as loss of insular ribbon, obscuration 
of the lenticular nucleus, loss of gray–white matter differentiation, 
FIgure 1 | CT scan of the head without contrast showing multilobar 
hypodensity in the right hemisphere (arrows).
FIgure 2 | (A) Axial non-contrast CT of the head demonstrates a left 
hyperdense middle cerebral artery sign indicative of acute thrombus (arrow). 
(B) CT scan of the head without contrast showing effacement of sulci and 
Sylvian fissure (arrowhead) and loss of distinction of the margins of the left 
lenticular nucleus (arrow).Frontiers in Neurology  | Neurocritical and Neurohospitalist Care    October 2010  | Volume 1  | Article 139  |  4
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Hyperglycemia and fever have been independently associated with 
increased risk of poor outcome in the setting of acute ischemic 
stroke. Any fever should be investigated for source as it may be 
the first sign of an infectious complication such as pneumonia. 
Follow-up brain imaging should be obtained at 24 h after treat-
ment, prior to the initiation of antithrombotics (antiplatelet agents 
or anticoagulants).
Additional complications from rt-PA include angioedema, which 
may cause partial airway obstruction, and, very rarely, myocardial 
rupture in patients with previous large myocardial infarctions.
Predictors of outcoMe after intravenous fibrinolysis
Older age, worse neurological deficits (i.e., higher NIHSS score) and 
disturbances of consciousness at presentation, higher admission 
blood glucose level, and early ischemic changes and hyperdense 
middle cerebral artery sign on baseline CT scan are the main pre-
dictors of poor outcome upon initial evaluation (NINDS rt-PA 
Stroke Study Group , 1995; Bruno et al., 2002; Heuschmann et al., 
2004; Qureshi et al., 2006; Wahlgren et al., 2008b; Mateen et al., 
2009). Time to fibrinolysis has a strong inverse association with 
functional outcome across strokes of different severity (Marler 
et al., 2000; Hacke et al., 2004). Hyperglycemia and intracranial 
hemorrhage predict hyperacute clinical worsening after fibrinolysis 
(Leigh et al., 2004). Lack of improvement at 24 h portends worse 
outcome at 3 months (Saposnik et al., 2004). Hyperglycemia, time 
to fibrinolytic therapy, and cortical involvement have been asso-
ciated with lack of improvement during the first day (Saposnik 
et al., 2004). The detrimental effects of hyperglycemia may be at 
least partially explained by lower rates of recanalization, probably 
related to a hyperglycemia-induced decrease in fibrinolytic activity 
(Ribo et al., 2005).
The main predictors of symptomatic intracranial hemorrhage 
are older age – although intravenous rt-PA can be administered 
to selected octogenarians and even non-egenarians with accept-
able safety – (Sylaja et al., 2006; Mateen et al., 2010), higher initial 
NIHSS, larger area of ischemia, and higher blood glucose lev-
els (Kidwell et al., 2002; Hacke et al., 2004; Albers et al., 2006). 
Longer time to fibrinolysis has been associated with higher risk of 
intracranial hemorrhage in some(Kidwell et al., 2002) but not all 
studies (Hacke et al., 2004). Higher systolic blood pressure may 
also increase the risk of intracranial hemorrhage (Wahlgren et al., 
2008b), but especially when currently recommended parameters 
for blood pressure controlled are not respected. Other protocol 
violations, most notably the use of antithrombotic agents dur-
ing the first 24 h, can markedly increase the risk of hemorrhage 
(Katzan et al., 2000).
novel strategies for intravenous fibrinolysis
selection of candidates for intravenous fibrinolysis using 
PenuMbral iMaging
There is strong physiological rationale to support the concept that 
imaging of the ischemic penumbra with MRI diffusion-weighted 
(DWI) and perfusion-weighted (PWI) or CT perfusion (CTP) can 
extend the therapeutic window for reperfusion therapies, including 
fibrinolysis. Proponents of this model argue that documentation of 
persistent ischemic penumbra (i.e., hypoperfused but salvageable 
tissue) should represent a solid indication for reperfusion treatments 
ideally guided by a written protocol to ensure optimal care and 
avoid risks. Patients should be kept on cardiac telemetry for at 
least the first 24 h.
Neurologic assessments and blood pressure measurements should 
be performed every 15 min during the infusion, followed by every 
30 min for the first 6 h, and then hourly until 24 h after treatment. The 
rationale for such close blood pressure monitoring is that excessive 
hypertension in patients treated with intravenous rt-PA is associated 
with the development of symptomatic hemorrhagic transformation. 
Hypertension in the 24 h post-fibrinolysis is preferably treated with 
intravenous labetalol or nicardipine infusion. If systolic blood pres-
sure exceeds 230 mm Hg or diastolic blood pressure exceeds 120 mm 
Hg, intravenous continuous infusions of antihypertensives (e.g., 
sodium nitroprusside) should be considered. If the patient devel-
ops severe headache, vomiting, or acute refractory hypertension 
(BP >180/110), an emergency head CT should be obtained.
Bleeding complications in general and intracranial hemorrhage 
in particular are the most common and feared adverse events after 
intravenous fibrinolysis. Yet, disabling or fatal intracranial hemor-
rhages after fibrinolysis typically occur in older patients with severe 
deficits and large areas of ischemia at presentation (Albers et al., 
2006; Saver, 2007). In other words, severe brain hemorrhages usu-
ally complicate fibrinolytic therapy in patients who already had very 
poor prognosis from presentation. As a consequence, few patients 
are actually harmed by intravenous rt-PA (number needed to harm 
has been estimated to be 126 for disabled or fatal outcome and 
36.5 for worsened outcome among patients treated within 3 h of 
symptom onset) (Saver, 2007).
Strict monitoring of blood glucose (with insulin as needed 
to  maintain  levels  between  140  and  180  mg/dL)  and  avoid-
ance of hyperthermia are essential measures of supportive care. 
Table 3 | Management of arterial hypertension in patients with acute 
ischemic stroke who are candidates for fibrinolysis.
Before fibrinolysis
If SBP >185 mm Hg or DBP >110 mm Hg
  Labetalol 10–20 mg IV over 1–2 min (may repeat once)
or
  Nicardipine infusion at 5–15 mg/h
If BP controlled, administer fibrinolysis
  If BP still >185/110 mm Hg, do NOT proceed with fibrinolysis
After fibrinolysis
If SBP 180–230 mm Hg or DBP 105–120 mm Hg
  Labetalol 10–20 mg IV over 1–2 min, 
  may repeat every 10–20 min up to 300 mg over 24 h
or
  Labetalol 10–20 mg IV followed by infusion at 2–8 mg/min
or
  Nicardipine infusion at 5–15 mg/h
If SBP >230 mm Hg or DBP >120 mm Hg
  Sodium nitroprusside infusion at 0.5–3 mcg/kg/min (doses of up 
  to 10 mcg/kg/min can be safely administered for up to 10 min)
This  protocol  also  applies  to  other  forms  of  reperfusion  therapy  apart  from 
intravenous rt-PA.
BP , blood pressure; SBP , systolic blood pressure; DBP , diastolic blood pressure.www.frontiersin.org  October 2010  | Volume 1  | Article 139  |  5
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come (defined as modified Rankin score ≤2 at 90 days). The rate 
of symptomatic intracranial hemorrhage was quite low (4%) and 
the risk of this complication did not correlate with baseline volume 
of restricted diffusion. In addition to DWI-PWI mismatch, there 
has been some interest in whether a clinical-diffusion mismatch 
(CDM, the comparison of severity of clinical deficits measured by 
NIHSS and area of restricted diffusion on MRI) can select patients 
for thrombolytic therapy. This was not supported in a substudy of 
EPITHET, in which there was no increased benefit from rt-PA in 
patients with CDM (Ebinger et al., 2009).
A recent study compared intravenous tenecteplase administered 
between 3 and 6 h from symptom onset on patients with docu-
mented penumbra (defined by MRI with DWI-PWI or CTP) and 
vessel occlusion (defined by non-invasive angiogram) versus control 
patients treated with intravenous rt-PA within 3 h according to cur-
rent guidelines (Parsons et al., 2009). Although the relatively small 
size of the study (n = 50, included only 15 treated with tenecteplase) 
and methodological limitations preclude definite conclusions, the 
high degrees of reperfusion (74%) and rates of recanalization (10/15 
cases) among patients selected on the basis of penumbral imaging 
was promising. Pilot trials testing intravenous desmoteplase between 
3 and 9 h from symptom onset in patients with DWI-PWI mis-
match on baseline MRI had shown encouraging results (Hacke et al., 
2005; Furlan et al., 2006). However, the larger DIAS-2 study did not 
confirm this benefit (Hacke et al., 2009). A preponderance of mild 
strokes with small core lesions and mismatch volumes may have 
limited the power of DIAS-2 to detect some therapeutic effect.
An ongoing trial (MR RESCUE) is assessing the value of endovas-
cular reperfusion within 3–8 h of symptom onset among patients 
with DWI-PWI mismatch on MRI. At this point, we still do not 
have sufficient information to recommend the use of penumbral 
imaging to select patients for fibrinolysis in clinical practice.
intra-arterial fibrinolysis and bridging theraPy
The study and application of endovascular reperfusion therapies for 
acute ischemic stroke has strong advocates. Unfortunately, available 
evidence is highly promising but not conclusive. Therefore, endovas-
cular interventions for acute brain ischemia cannot be considered 
standard of care. This is a brief review of the most important infor-
mation on intra-arterial fibrinolysis and combined intravenous and 
intra-arterial therapy (also known as bridging therapy).
The PROACT II study provides the best evidence that intra-
arterial fibrinolysis can improve patient outcomes (Furlan et al., 
1999). This was a rigorously designed, multi-center (54 centers in 
USA and Canada), randomized, open-label study with blinded out-
come assessment which enrolled 180 patients with angiographically 
proven middle cerebral artery occlusion and stroke symptoms for 
less than 6 h to receive intra-arterial pro-urokinase over 2 h plus 
intravenous heparin versus intravenous heparin alone (all patients 
received heparin for 4 h). Mechanical disruption of the clot was 
not allowed. Intra-arterial fibrinolysis resulted in recanalization in 
66% of cases. Favorable functional outcome (defined as modified 
Rankin score of ≤2) at 90 days occurred in 40% of patients treated 
with intra-arterial fibrinolysis versus 25% of patients in the control 
group (P = 0.04; number needed to treat = 7). These results were 
quite remarkable considering that participating patients had severe 
deficits at presentation (median NIHSS = 17). The rate of symp-
regardless of duration of symptoms. A comparison of CTP sequences 
of mean transit time, cerebral blood flow, and cerebral volume may 
identify whether there is salvageable ischemic penumbra or if the 
infarct has been completed (Figure 3). Assuming that brain imaging 
can reliably recognize penumbral tissue and   discriminate patients at 
excessive risk for bleeding in the infarct core, the concept should be 
valid. However, these assumptions remain to be proven.
DEFUSE was a prospective observational study of 74 patients 
treated with intravenous rt-PA between 3 and 6 h after symp-
tom onset (Albers et al., 2006). All patients underwent MRI with 
DWI-PWI and MR angiogram before and a few hours after fibri-
nolysis, but all patients were treated regardless of the radiologi-
cal findings. The investigators found that patients with a “target 
mismatch profile” (i.e., large areas of hypoperfusion with much 
smaller areas of restricted diffusion) benefited greatly from fibri-
nolysis if they achieved recanalization. Conversely, patients with 
very large areas of restricted diffusion had unacceptably high risks 
of intracerebral bleeding.
The randomized trial EPITHET assigned 101 patients to receive 
intravenous rt-PA or placebo 3–6 h after stroke onset (Davis et al., 
2008). All patients were studied with MRI with DWI-PWI before 
and a few days after treatment, but the radiological findings did 
not affect treatment assignment. DWI-PWI was present in 86% of 
patients. Reperfusion occurred in 39% of mismatch patients and 
these patients had less infarct growth and better functional out-
FIgure 3 | CT perfusion scan of the head demonstrates findings 
consistent with large ischemic penumbra. Decreased cerebral blood flow 
(A), preserved cerebral blood volume (B), and prolonged time to peak (C) and 
mean transit time (d) in the left middle cerebral and bilateral anterior cerebral 
artery distributions are shown.Frontiers in Neurology  | Neurocritical and Neurohospitalist Care    October 2010  | Volume 1  | Article 139  |  6
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pilot study had better   outcomes than the rt-PA-treated patients in the 
NINDS study despite longer time to start of intravenous fibrinoly-
sis and much worse initial stroke severity. The rate of symptomatic 
intracranial hemorrhage was nearly 10%, but 3 month mortality was 
actually lower than expected (16%). IMS III is randomizing patients 
to standard intravenous rt-PA versus combined intravenous/intra-
arterial approach (including mechanical embolectomy).
clinical Pearls
•	 Intravenous	 fibrinolysis	 is	 an	 effective	 treatment	 for	 acute	
ischemic stroke for up to 4.5 h after symptom onset.
•	 Time	from	symptom	onset	to	fibrinolytic	therapy	is	the	most	
important determinant of the success of treatment; the chan-
ces of favorable recovery diminish with each minute lost.
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